Monuril (Fosfomycin Trometamol)

Fosfomycin trometamol inhibits the bacterial enzyme MurA, blocking the first step of peptidoglycan synthesis. By preventing formation of N‑acetylmuramic acid, it disrupts cell‑wall construction, leading to bacterial death and eradication of the infecting uropathogens.

The exact dose of Monuril is determined by the prescribing clinician based on the patient’s condition, age, renal function and local guidelines. In most cases a single oral dose is prescribed, but the specific amount must be confirmed by the healthcare professional.

Safety data for fosfomycin trometamol in pregnancy and lactation are limited. It is generally avoided during pregnancy unless the potential benefit justifies the risk, and breastfeeding mothers should discuss possible infant exposure with their physician before use.

To order Monuril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with nitrofurantoin or trimethoprim‑sulfamethoxazole, fosfomycin offers a single‑dose regimen and retains activity against many resistant strains. However, its spectrum is narrower, and local resistance patterns should guide selection. Clinicians often choose the agent with the best susceptibility profile for the patient’s pathogen.

Monuril tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Monuril is taken orally as a single tablet with a full glass of water. It is usually administered on an empty stomach, at least 30 minutes before or after meals, to maximise absorption. No additional dosing is required unless directed by a physician.

The most serious adverse reactions include severe allergic responses such as anaphylaxis, rare skin disorders like Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they experience rash, difficulty breathing, persistent diarrhea or any signs of a severe reaction.

Monuril should be avoided in individuals with a known hypersensitivity to fosfomycin or any component of the formulation. It is also contraindicated in patients with severe renal impairment where dosing cannot be adjusted safely, and in those where the infection is not caused by a susceptible organism.